STAT+: 5 burning questions on Trump’s latest deals with drugmakers

The Trump administration on Monday announced a second group of pharmaceutical companies had pledged to lower drug prices to levels comparable to those in other nations. President Trump touted the deals from the White House as one of the most important health care breakthroughs, but the details are not public. Key open questions include whether the companies would avoid tariffs or otherwise mandatory Medicare drug pricing pilot programs; the White House did not respond to requests for comment.